Evidence map›Paper›PMID 31352162›Full record

ArticleBlood cells, molecules & diseases2019

Combined genetic disruption of K-Cl cotransporters and Gardos channel KCNN4 rescues erythrocyte dehydration in the SAD mouse model of sickle cell disease.

Boris E Shmukler, Alicia Rivera, Parul Bhargava, Katherine Nishimura, Ann Hsu, Edward H Kim, Marie Trudel, Marco B Rust, Christian A Hubner, Carlo Brugnara and 1 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Blood cells, molecules & diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Magnesium homeostasis in deoxygenated sickle erythrocytes is modulated by endothelin-1 via NaFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Boris E ShmuklerRenal Division and Vascular Biology Research Center, Beth Israel Deaconess Medical Center, Boston, MA, United States of America; Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA 02115, United States of America.
Alicia RiveraRenal Division and Vascular Biology Research Center, Beth Israel Deaconess Medical Center, Boston, MA, United States of America; Department of Medicine, Harvard Medical School, Boston, MA 02115, United States of America; Department of Pathology, Harvard Medical School, Boston, MA 02115, United States of America.
Parul BhargavaDepartment of Laboratory Medicine, UCSF, San Francisco, CA, United States of America.
Katherine NishimuraRenal Division and Vascular Biology Research Center, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
Ann HsuRenal Division and Vascular Biology Research Center, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
Edward H KimRenal Division and Vascular Biology Research Center, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
Marie TrudelInstitut de Recherches Cliniques de Montreal, Molecular Genetics and Development, Faculte de Medecine, Universite of Montreal, Montreal, Quebec, Canada.
Marco B RustInstitute of Physiological Chemistry, Philipps-Universität Marburg, Marburg, Germany.
Christian A HubnerInstitute of Human Genetics, Universitatsklinikum Jena, Jena, Germany.
Carlo BrugnaraDepartment of Laboratory Medicine, Boston Children's Hospital, Boston, MA 02115, United States of America; Department of Pathology, Harvard Medical School, Boston, MA 02115, United States of America.
Seth L AlperRenal Division and Vascular Biology Research Center, Beth Israel Deaconess Medical Center, Boston, MA, United States of America; Department of Medicine, Harvard Medical School, Boston, MA 02115, United States of America. Electronic address: salper@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USHarvard University · USBoston Children's Hospital · USJena University Hospital · DEMontreal Clinical Research Institute · CAPhilipps University of Marburg · DEUniversity of California, San Francisco · US

Funding

RBC Ion Transporters as Hemoglobinopathy Risk ModifiersR01HL077765 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ALPER, SETH LEO · 2006 to 2009
$1.6M
NHLBI NIH HHS R01 HL077765
6 · The paper itself

Abstract

Excessive red cell dehydration contributes to the pathophysiology of sickle cell disease (SCD). The densest fraction of sickle red cells (with the highest corpuscular hemoglobin concentration) undergoes the most rapid polymerization of deoxy-hemoglobin S, leading to accelerated cell sickling and increased susceptibility to endothelial activation, red cell adhesion, and vaso-occlusion. Increasing red cell volume in order to decrease red cell density can thus serve as an adjunct therapeutic goal in SCD. Regulation of circulating mouse red cell volume and density is mediated largely by the Gardos channel, KCNN4, and the K-Cl cotransporters, KCC3 and KCC1. Whereas inhibition of the Gardos channel in subjects with sickle cell disease increased red cell volume, decreased red cell density, and improved other hematological indices in subjects with SCD, specific KCC inhibitors have not been available for testing. We therefore investigated the effect of genetic inactivation of KCC3 and KCC1 in the SAD mouse model of sickle red cell dehydration, finding decreased red cell density and improved hematological indices. We describe here generation of mice genetically deficient in the three major red cell volume regulatory gene products, KCNN4, KCC3, and KCC1 in C57BL6 non-sickle and SAD sickle backgrounds. We show that combined loss-of-function of all three gene products in SAD mice leads to incrementally increased MCV, decreased CHCM and % hyperchromic cells, decreased red cell density (phthalate method), increased resistance to hypo-osmotic lysis, and increased cell K content. The data show that combined genetic deletion of the Gardos channel and K-Cl cotransporters in a mouse SCD model decreases red cell density and improves several hematological parameters, supporting the strategy of combined pharmacological inhibition of these ion transport pathways in the adjunct treatment of human SCD.

Indexed as

Anemia, Sickle CellAnimalsCell SizeDehydrationDisease Models, AnimalErythrocytesHumansIntermediate-Conductance Calcium-Activated Potassium ChannelsK Cl- CotransportersMiceSymportersIntermediate-Conductance Calcium-Activated Potassium ChannelsK Cl- CotransportersKcnn4 protein, mouseSlc12a6 protein, mouseSymportersOsmotic fragilityPotassium channelPotassium transporterRed blood cellSplenomegaly

Identifiers

PMID31352162
PMCPMC6744291
OpenAlexW2964197897

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.